Fourteen subjects with EWSR1-NFATc2 fusion positive sarcoma were identified in the Foundation Medicine FoundationCore® (FMI) research database from a total of 1024 EWSR1 fusions, resulting in an overall prevalence of 1.4% among EWSR1 fusion positive sarcomas. Here, NFATC2 is linked to sarcoma.